drugset / Trial / NCT01624766
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of everolimus when given together with anakinra or denosumab in treating participants with cancers that have spread to other places in the body and have come back or aren't responding to treatment. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and the spread of cancer. Monoclonal antibodies, such as denosumab, may interfere with the ability of tumor cells to grow and spread. Giving everolimus and anakinra or denosumab may work better in treating participants with advanced cancers.
Timeline
- Start
- 2012-06-19
- Primary completion
- 2021-02-24
- Completion
- 2021-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Denosumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Everolimus | Small molecule | — | Oral |